Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Plans $4.3M Public Stock Offering

NEW YORK (GenomeWeb) – Interpace Diagnostics disclosed yesterday that it aims to raise roughly $4.3 million through the public offering of 630,000 shares of its common stock at a price of $6.81 per share.

Proceeds of the offering will be used for working capital, repayment of indebtedness, and general corporate purposes, the company said in a filing with the US Securities and Exchange Commission. Interpace said it will have approximately 2.8 million shares outstanding after the close of the offering.

During midday trading on the Nasdaq today, shares of Interpace were down 6.4 percent to $6.40.

Earlier this week, Interpace announced that it had signed a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds. Last month, the company entered into a stock purchase deal to raise $1.7 million, and effected a 1-for-10 reverse stock split in a bid to keep its shares listed on the Nasdaq.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.